Merck & Co Inc

NYSE:MRK  
77.54
+1.01 (+1.32%)
4:22:36 PM EDT: $77.33 -0.21 (-0.27%)
Products, Regulatory

Merck Presents New Data From Ongoing Phase 2A Clinical Trial Evaluating The Safety, Tolerability And Pharmacokinetics Of Investigational, Once-Monthly, Oral Islatravir For Hiv-1 Prevention At Ia

Published: 07/20/2021 10:10 GMT
Merck & Co Inc (MRK) - Merck Presents New Data From Ongoing Phase 2a Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of Investigational, Once-monthly, Oral Islatravir for Hiv-1 Prevention at Ias 2021.
Merck & Co Inc - Results From This Study Support Safety Profile of Oral Islatravir Prep Regimen Through 24 Weeks Versus Placebo.
Merck & Co Inc - There Were No Serious Drug-related Aes in People Who Received Islatravir.